✔Mango is a Mangoceuticals flagship product that's positioned to tap into the sexual health supplement market and is expected to reach $4.2 billion from $2.54 billion as of last year.
✔The men's health sector is ripe with attractive opportunities as it continues to grow at a compound annual growth rate of 15% by 2029. The rapid growth has to do with a rise in men's health awareness and a shift in societal norms.
✔Mangoceuticals is one of the few companies well poised to take advantage of the huge opportunity presented by the erectile dysfunction condition.
✔Mangoceuticals secures its position as the official sponsor of Barstool Sports' "Only Stans" Podcast. With an impressive listener base of over 320,000 per episode, this partnership opens up exciting promotional opportunities.
✔ Having successfully concluded a $5 million public offering in March, Mangoceuticals stands firm with a strong financial footing to bring its flagship ED product to market. The company is utilizing the freshly acquired funds to support marketing initiatives and cover various expenses, aiming to expand its outreach to a wider target audience.
✔The men's health sector market is a multi-billion-dollar industry with significant growth potential. With a compound annual growth rate surpassing 10%, this market presents abundant opportunities for expansion.
Mangoceuticals, Inc. is a dedicated company specializing in the development, marketing, and sale of a diverse range of men's health and wellness products and services through a secure telemedicine platform. Recognizing the expanding market for men's wellness telemedicine offerings, particularly in the field of erectile dysfunction (ED), the company has successfully launched a new line of ED products branded as "Mango" (a play on "Man Go").
The sexual health supplement market is expected to reach $4.2 billion from $2.54 billion as of last year. The men's health sector is ripe with attractive opportunities as it continues to grow at a compound annual growth rate of 15% by 2029. The rapid growth has to do with a rise in men's health awareness and a shift in societal norms.
Mango is a Mangoceuticals flagship product that's positioned to tap into the sexual health supplement market and is expected to reach $4.2 billion from $2.54 billion as of last year. The groundbreaking solution is designed to address men's unique concerns with erectile dysfunction (ED) issues.
The expertly formulated solution ensures a superior experience for customers as it contains the active ingredient Cialis supplemented by innovative formulation of oxytocin and LArginine. Therefore, it is a rapidly dissolving tablet that's able to hit the bloodstream quicker and faster for optimum results.
The inability to rise to the occasion and sustain a robust penile erection is one of the challenges facing men worldwide. Likewise, Mangoceuticals has set out to address the issue with its proprietary solution that's already eliciting strong interest owing to its ability to help men achieve optimum performance.
Backed by its safe, secure, and convenient telehealth platform MangoRX, Mangoceuticals has made impressive strides to target people struggling with erectile dysfunction.
The telehealth platform has made it easy for most men to easily access the product without leaving their homes. By eliminating the need for in-person doctor visits, it established itself as a discreet and accessible solution for men's sexual needs.
The product is already available in more than 44 states, including Nevada and the District of Columbia. The expansion marks an important milestone in Mangoceutical's bid to target a wider target market. In addition, it enhances the prospect of strengthening the revenue streams to tap into the multi-billion opportunity in the global ED market.
MGRX stock price moving above the 50-day moving average amid a significant increase in the total traded shares affirms strong buying pressure. With the stock trading for about $1.80 a share, after finally breaking over the $1.68 resistance, there is no doubt it could explode over $2.00 as it remains highly undervalued at its current valuation.
⋅ RSI is still low after closing the previous week up 14%.
⋅ Volume increasing on the way up.
⋅ Lots of support in the $1.30-$1.40 range.
⋅ Broke over $1.68 resistance which has been a big resistance in the past. This should act as support now.
or
$1.30-$1.40
#1: $2.10
#2: $2.40
#3: $3.18
Sexual health issues have always been a significant concern in the healthcare industry. Similarly, erectile dysfunction (ED), infertility and other sexual problems continue to spur growth in the sexual health supplement market.
The men's health sector is ripe with attractive opportunities as it continues to grow at a compound annual growth rate of 15% by 2029. The rapid growth has to do with a rise in men's health awareness and a shift in societal norms.
Emphasizing self-care, the need to enhance sexual health among men is also unlocking new opportunities. Amid the increased men's health awareness, Mangoceuticals (NASDAQ:MGRX) has emerged as an ideal play for any investor eyeing exposure in the burgeoning sector.
The company is already tapping into the opportunity presented by sexual health issues. Focused on developing, marketing, and selling men's wellness products and services, the company is playing its role in meeting the growing demand for male-centric wellness.
Driven by its mission to improve the lives of men and their partners by creating high-quality sexual health products, Mangoceuticals is slowly emerging as a force to reckon with. The company already boasts of an array of sexual health products that puts it at the center of the expected growth in the industry.
Mango Erectile Dysfunction Solution
Mango is a Mangoceuticals flagship product that's positioned to tap into the sexual health supplement market and is expected to reach $4.2 billion from $2.54 billion as of last year. The groundbreaking solution is designed to address men's unique concerns with erectile dysfunction (ED) issues.
The expertly formulated solution ensures a superior experience for customers as it contains the active ingredient Cialis supplemented by innovative formulation of oxytocin and LArginine. Therefore, it is a rapidly dissolving tablet that's able to hit the bloodstream quicker and faster for optimum results.
The inability to rise to the occasion and sustain a robust penile erection is one of the challenges facing men worldwide. Likewise, Mangoceuticals has set out to address the issue with its proprietary solution that's already eliciting strong interest owing to its ability to help men achieve optimum performance.
Mangoceuticals is one of the few companies well poised to take advantage of the huge opportunity presented by the erectile dysfunction condition. Backed by the highly effective Mango product, the company is more than ready to help men with ED conditions rise to the occasion and generate significant value in return.
The MangoRXtelehealth platform further strengthens the company's bid to reach a broader target market by targeting the millions of men that suffer in silence. Its aggressive marketing campaign through social networks continues to bear fruits going by the millions of views.
The solid underlying fundamentals underscore why MGRX stock is a solid buy going by the tremendous opportunities in the multi-billion men's health sector market. With the market growing at a compound annual growth of more than 10%, there is room for tremendous opportunities for growth.
On the other hand, MGRX appears highly undervalued as the stock is trading for pennies. Nevertheless, there has been a significant change in market sentiments in recent weeks, signaling growing interest amid solid growth metrics and long-term prospects.
MGRX stock price moving above the 50-day moving average amid a significant increase in the total traded shares affirms strong buying pressure. With the stock trading for about $1.6 a share, there is no doubt it could explode as it remains highly undervalued at its current valuation.
Jacob Cohen is a serial entrepreneur, corporate finance and executive management professional with over 20 years of investment banking and capital markets experience having started and growing multiple companies in various industry sectors including marketing, advertising, healthcare, IT and financial services. Prior to founding the Company, Mr. Cohen was the co-founder and managing partner of several boutique investment bank and strategic advisory firms where he advised both early and later stage companies in raising capital in the form of debt and/or equity and in both private and public markets.
Prior to his experiences in investment banking, Mr. Cohen served as the Chief Financial Officer of The Renewed Group, Inc., a manufacturer, wholesaler and retailer of eco-friendly and sustainable apparel primarily made from recycled textiles and under the brand name REUSE JEANS from 2010 through the end of 2013. Further, Mr. Cohen served from 2008 through 2010 as Executive Vice President and Controller of Metiscan, Inc., a publicly traded company, and as the President and Chief Executive Officer of one of its subsidiaries, Shoreline Employment Services, Inc. During his tenure at Metiscan, Mr. Cohen was instrumental in restructuring, reorganizing and operating the company and its five subsidiaries, and successfully raised over $8 million in equity financing for growth capital. Mr. Cohen also spearheaded the company’s financial audit process and managed its various filings with the SEC.
From 2007 through 2008, Mr. Cohen served as the Chief Operating Officer of Artfest International, which he assisted in taking public at the end of 2007. Throughout his career, Mr. Cohen was involved in starting many new ventures, including The AdvertEyes Network, a digital signage advertising company where he served as founder and CEO. Other positions include investment advisor and institutional equity research analyst for Solomon Advisors and Huberman Financial, securities broker-dealers, from 2003 through 2005, and investment banker for Allegiance Capital, a middle market investment bank specializing on mergers and acquisitions, from 2005-2007. Mr. Cohen holds a Bachelor of Arts in International Economics and Finance from Brandeis University in Waltham, Massachusetts.
Mr. Cohen has served as Chief Executive Officer of the Company since October 2021, as a director from October 2021 to present, and as Chairman from September 2022 to present. Mr. Cohen also currently serves as Chief Executive Officer and as a director of American International Holdings Corp (“American International”), a publicly traded company which is the majority owner and parent to Epiq Scripts, LLC, and which is the former sole owner of the Company, having fully divested its ownership in June 2022, and as Chief Executive Officer of Ronin Equity Partners, Inc., a private investment company, which role he has held since August 2016. Mr. Cohen also serves the Chief Executive Officer of Cohen Enterprises, Inc., a private investment company, which position he has held since November 2013.
Jonathan Arango is a Business Development Executive with more than 10 years of hands-on experience in pharmacy operations and management, business development, team management, and strategic relationship development. He has a history of driving significant revenue growth for companies in multiple sectors. Mr. Arango participates in numerous ambitious ventures, spanning multiple industries such as e-commerce, medical & health, restaurants, and cryptocurrency.
Mr. Arango has served as the Co-Founder, President and Director of the Company since October 2021. Prior to his appointment to the Company, Mr. Arango served as Chief Operating Officer of Murphy Rx LLC, a retail and specialty pharmacy based out of Murphy, Texas, which he previously owned, from June 2020 to March 2022. Prior to owning a pharmacy, Mr. Arango founded and served as CEO of Golden Heights Medical Consulting, a healthcare marketing agency that specialized in customer acquisition and medical ancillary services from February 2017 to January 2019. He also served as an independent contractor providing marketing and sales services from April 2015 to February 2017.
Before entering the healthcare industry, Mr. Arango ran an independent marketing and sales agency from 2013 to 2018 (A&J Marketing). A&J Marketing was contracted by multiple companies spanning different industries to generate and substantially scale revenue in multiple sectors. Industries included were Home Improvement, Oil & Gas, Health & Wellness, Professional Development, and E-commerce.
Mr. Johnston has served as Chief Financial Officer of the Company since October 2022. Since February 2015, Mr. Johnston has served as Audit Manager for Greentree Financial Group, Inc., an accounting and auditing firm. From August 1999 to September 2014, Mr. Johnston served as Chief Executive Officer of Peoplesway.com, Inc., a skincare and nutritional products company, and from August 1999 to present, Mr. Johnston has served as a member of the Board of Directors of Peoplesway.com, Inc. From January 1999 to July 1999, Mr. Johnston served as Chief Executive Officer of RMC Group, Inc., a skincare and nutritional products company. Prior to that, from April 1987 to January 1989, Mr. Johnston served as Vice President of Sales Administration at WeCare Distributors, Inc., a skincare and nutritional products company. Mr. Johnston received a Bachelor’s in Science in Business Administration from the University of North Carolina Charlotte.
Amanda Hammer has been a member of the MangoRx team since late 2022 and has been instrumental in launching and optimizing MangoRx’s eCommerce platform. She is a proven leader with a track record of success having recently completed a 4-year tenure at D Magazine Partners, a Dallas based multimedia company, where she held roles leading Audience Development, Brand, and Digital Operations, quickly rising to become the company’s first named Chief Operations Officer. Prior to that, Amanda worked in private equity consulting and assisting newly acquired business verticals with optimizing sales and marketing processes, improving subscription retention, and training new talent to enhance productivity and maximize revenue streams. Amanda obtained dual Bachelor of Arts degrees—in Graphic Design and Communication Studies—from the University of Iowa. She has also obtained a Negotiation and Leadership Certificate from Harvard Law School and is a recent graduate of the Texas Women’s Foundation Leadership Institute.
• https://www.mangoceuticals.com/corporate-governance
• https://www.mangoceuticals.com/press-releases
• https://stockanalysis.com/stocks/mgrx/company/
• https://www.mangoceuticals.com/
• https://www.mangorx.com/
• https://finance.yahoo.com/quote/MGRX/
DISCLAIMER
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of Stocks and Gains (https://stocksandgains.com) (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an auto dialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.html , as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which includes, but is not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. Owners and operators of the Publisher have been compensated One thousand dollars by bank wire transfer on 06/23/23 for the distribution of this advertisement about MGRX dated 06/26/23. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at mail@stocksandgains.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: Privacy Policy and Disclaimer.. By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.